Arbutin vs Kojic Acid vs Ethyl Ascorbyl Ether: Korean Whitening Actives for US Indie Brands Under MoCRA (2026)

By the ALTA MEET editorial team | K-beauty ODM consulting

Korean ODM chemists reach for a specific shortlist of tone-correcting actives that carries a regulatory pedigree US indie brands almost never think about. Three of the most common (alpha-arbutin, kojic acid dipalmitate, and ethyl ascorbyl ether) sit on the Korean Ministry of Food and Drug Safety (MFDS) functional cosmetic list for whitening/brightening claims, which means a Korean ODM can quote them into a formula with a fully documented efficacy paper trail. Bring the same formula into a US brand under MoCRA and the claim picture looks completely different. This piece walks you through when to pick each, how they compare on formulation risk, and what the FDA and MoCRA framework will actually let you say on the back label.

An MFDS whitening functional listing on the Korean side and a compliant MoCRA product listing on the US side are two different filing obligations that need to be reconciled before your label copy is finalized. Getting that reconciliation right is a legal exercise, not a marketing one, and it starts at ingredient selection.

Why compare these three specifically

Almost every "brightening" serum quote sheet a Korean ODM sends an indie US brand includes at least one of these three actives. They occupy the sweet spot between "publicly documented efficacy" and "stable enough to formulate at scale." Hydroquinone still shows up in derm-office grade compounds, but it is restricted for OTC cosmetic use in the US since 2020 and is barred from cosmetics under the EU CosIng annex (EU CosIng regulated substances). Tranexamic acid is popular but its Korean ODM adoption is skewed toward higher-cost anti-pigmentation clinicals rather than mass-brightening serums. That leaves alpha-arbutin, kojic acid derivatives, and vitamin C derivatives as the working set.

If you are sourcing from Korea, understanding the trade-offs among these three tells you three things at once: which one your ODM will happily formulate under an MFDS functional listing, which one raises stability red flags at the fill line, and which one lets you make the strongest US-market messaging without stepping into drug-claim territory.

The comparison at a glance

Numeric use-range guidance in the table reflects general formulation literature; your ODM's actual quoted percentage should sit inside the safety and efficacy envelope specific to their chosen supplier and processing method.

Alpha-arbutin, the safest brightening default

Alpha-arbutin is a synthetic isomer of arbutin, a hydroquinone glycoside originally found in bearberry. It works by slowly releasing hydroquinone into the skin as an enzymatic byproduct, which inhibits tyrosinase, the rate-limiting enzyme in melanin production (SCCS Opinion on alpha-arbutin). The Scientific Committee on Consumer Safety at the European Commission has repeatedly assessed alpha-arbutin as safe within specified upper limits for face and hand-use cosmetics.

From an ODM manufacturing standpoint, alpha-arbutin is the safest default because it is stable at near-neutral pH, does not oxidize in typical aqueous serum bases, and does not require the fill-line changes or nitrogen sparging that a vitamin C system might. If a Korean lab quotes you a "brightening" serum without asking a lot of process questions, you can usually bet alpha-arbutin is the active they are anchoring on.

The MFDS functional listing for whitening covers alpha-arbutin at a defined maximum concentration, which means your Korean ODM can legally market the finished product in Korea as a "whitening functional cosmetic" with a compliant efficacy dossier (MFDS Cosmetic Act functional list). The Korean efficacy paper trail, usually a 4- to 8-week human panel with a colorimeter reading and a photograph protocol, does not automatically transfer to US claims, but it does give your marketing team something credible to reference in press material.

Where it fits: first-time brightening SKUs, sensitive-skin lines, formulas where reformulation cost and stability testing budget are tight. It is also the easiest for a US-based regulatory reviewer to sign off on because the toxicology dossier is publicly available in EU SCCS opinions.

Kojic acid dipalmitate, the ester that made kojic acid formulatable

Free kojic acid is a fermentation product first isolated from Aspergillus oryzae, the same organism used in koji fermentation for miso and soy sauce. It is a strong tyrosinase inhibitor but has a real formulation problem: it browns on exposure to air and metal ions, and it can destabilize otherwise-clean serum bases within weeks.

Kojic acid dipalmitate is the palmitic ester form that solves this. The two palmitate groups block the phenolic hydroxyl positions that participate in oxidation, giving the molecule a shelf life comparable to a normal cosmetic active while retaining useful tyrosinase inhibition in-skin as the ester is slowly hydrolyzed by cutaneous esterases.

Korean ODMs almost universally quote the dipalmitate form rather than free kojic acid for indie brand programs. When you see a Korean quote sheet listing "kojic acid" at a low single-digit weight-percent, ask the ODM explicitly: "Is this the dipalmitate ester or the free acid?" The pricing, packaging spec, and stability testing plan all change based on the answer.

Where it fits: brightening-plus-antioxidant lines that want a story beyond arbutin, formulas that are not building around a vitamin C anchor. Also useful when the brand wants to reference the fermentation heritage narrative, Aspergillus koji has a story that resonates with the growing consumer interest in fermented skincare that Cosmetics Business has covered as a durable K-beauty theme (Cosmetics Business fermentation trend coverage).

Ethyl ascorbyl ether, the vitamin C derivative that survives a Korean fill line

L-ascorbic acid is the gold-standard vitamin C molecule in dermatology literature, but it is notoriously difficult to formulate at scale. It requires pH under 3.5 for stability, oxidizes rapidly on exposure to air, water, or metal ions, and turns brown in weeks if the packaging is not fully airless. For a Korean ODM running large batch fills into standard PET or glass pumps, L-ascorbic acid is a headache.

Ethyl ascorbyl ether (also called 3-O-ethyl ascorbic acid) is a vitamin C derivative that keeps most of the L-ascorbic-acid mechanism, it is converted to free ascorbic acid by cutaneous enzymes after topical application, while being stable at a much broader pH range and much more resistant to oxidation (PubMed ethyl ascorbyl ether skin bioavailability).

For an indie US brand that wants a "vitamin C serum" story without the airless-pump, refrigerated-shipping, batch-color-drift management that L-ascorbic acid demands, ethyl ascorbyl ether is the pragmatic choice. It also stacks well with alpha-arbutin in the same formula, one hitting tyrosinase, one hitting oxidative pathways.

Where it fits: vitamin-C-branded SKUs that need to survive normal warehouse conditions, dual-mechanism brightening lines, and any product where "vitamin C" is the front-of-pack story but you cannot afford refrigerated stability trials.

The founder decision matrix

A quick note from Liz, I'm Liz Song, and I run altameet from Manhattan, NYC, where we help US indie beauty founders scope Korean ODM programs. Nine times out of ten when a founder shows me a "brightening serum" quote from a Korean lab, the active on the line item is alpha-arbutin, and they had no idea that was a considered choice by the lab. Understanding why your ODM picked what they picked is the difference between owning your brand story and defending it. If you want a quick gut-check on which of these three fits your positioning, I will give you 15 minutes free. Book a call with Liz or email liz@altameet.com.

What MoCRA actually lets you say on the label

This is where a lot of US indie brands make expensive mistakes. Korea's MFDS functional cosmetic framework lets a Korean ODM say a product is a "whitening functional cosmetic" on the Korean SKU because the efficacy testing has been reviewed and the ingredient sits on a pre-approved list. That legal status does not port to the US market (FDA Cosmetics Labeling Guide).

Under the FDA framework and the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), a product that claims to "whiten" or "lighten skin" through a pharmacological mechanism may be regulated as a drug rather than a cosmetic. The line the FDA has consistently drawn: cosmetic claims describe appearance ("brighter", "more even-looking", "reduces the appearance of dark spots"), while drug claims describe structural or functional effect ("lightens skin", "inhibits melanin production", "treats hyperpigmentation") (FDA cosmetics vs drugs guidance).

Your label copy should live entirely on the appearance side of that line, even if the Korean quote sheet you signed talks about tyrosinase inhibition. Practical translations:

• "Whitening serum" → "Brightening serum" or "Even-tone serum"
• "Reduces melanin production" → "Reduces the look of dark spots"
• "Treats hyperpigmentation" → "For an even-toned appearance"
• "Anti-melanogenesis complex" → "Brightening blend"

Under MoCRA, you also need to have your facility registered and each product listed with the FDA, submit safety substantiation, and comply with adverse event reporting (FDA MoCRA implementation). None of that changes based on which of these three actives you pick, but the substantiation file will look different in each case, arbutin has the broadest EU/global regulator paper trail, EAE has the most peer-reviewed skin-bioavailability data, kojic dipalmitate has the strongest cosmetic-chemistry stability literature.

Formulation risk and cost drivers

The three cost drivers on a whitening serum quote sheet are formula complexity, fill-line changeover, and packaging spec. Each active pushes on those levers differently.

Alpha-arbutin is the cheapest to formulate. Cold-process compatible in most aqueous serum bases, no nitrogen sparging, no airless pump required. Standard PET dropper or pump packaging is fine. Stability testing runs a normal 12-week accelerated protocol.

Kojic acid dipalmitate requires a slightly warmer processing temperature to disperse the ester properly and often benefits from a small percentage of a compatible emollient. Fill-line and packaging spec are similar to arbutin. Stability testing occasionally flags slight yellow drift over 12 weeks even in the ester form, which the ODM will color-correct in the formula with a low-level chelator.

Ethyl ascorbyl ether sits between the two. It is far less demanding than L-ascorbic acid, no need for a pH-3 formulation, no need for airless pumps, no refrigerated shipping, but it does benefit from careful packaging choice (opaque or amber preferred) and slightly tighter oxygen management during fill. Expect stability testing to include a color-drift photograph protocol.

For an indie US brand budgeting first-batch production, expect the packaging spec differences to matter more than the active raw material cost. The dropper bottle you pick, the wall thickness of the pump, and the outer secondary packaging spec together drive more of the final delivered per-unit cost than the choice among these three actives.

The stack question

Founders often ask whether they can put all three in the same formula. The technical answer is yes, none of these three has a hard incompatibility with the others. But the marketing answer is usually no: a serum with three tone-correcting actives at meaningful percentages costs more, requires more stability work, and dilutes the story on the back label.

The pragmatic pattern most Korean ODMs recommend for an indie brand's first brightening SKU is a two-active stack. Common combinations:

• Alpha-arbutin + niacinamide (safe, cheap, well-supported)
• Ethyl ascorbyl ether + alpha-arbutin (dual mechanism, vitamin C story)
• Kojic acid dipalmitate + niacinamide (fermented heritage angle)

Adding a peptide, a botanical extract like centella asiatica, or a hydrator like polyglutamic acid gives your formula a differentiated position without stacking a third tone-correcting active on top.

What to ask your Korean ODM before signing

If you are getting quote sheets from a Korean ODM and want to make sure you understand what you are buying, five questions get you most of the way there:

1. Which specific ingredient INCI name is the "whitening" active in the formula? (Alpha-arbutin, kojic acid dipalmitate, ethyl ascorbyl ether, or something else?)
2. What is the target concentration and is it inside the MFDS functional cosmetic listed range?
3. What efficacy data do you have on file for this concentration in this formula base? (Look for human panel colorimeter data, not just cell-line studies.)
4. What accelerated and real-time stability protocols are you running, and is there a color-drift acceptance spec written into the finished product spec?
5. What is the packaging spec you are quoting the price at, and will the price hold if I switch to airless / amber / heavier-wall packaging?

That five-question exchange tells you whether you are getting a professional program or a copy-paste template, and it gives you the information you need to translate the Korean regulatory context into a US-compliant marketing story on your side.

Frequently asked questions

Is kojic acid safe? I have seen consumer concerns. Consumer concerns are usually about the free-acid form's oxidation potential and about a small number of animal-model studies on oral exposure that do not translate to topical cosmetic use. The dipalmitate ester used in Korean ODM formulas is a distinct molecule from free kojic acid and has been assessed as safe in the topical concentrations typically formulated. Reviewing the SCCS opinion series is a good starting point for a regulatory brief (EU Scientific Committee on Consumer Safety).

Can I import a Korean SKU that is labeled as a whitening functional cosmetic and sell it in the US as-is? No. You will need to re-label to remove drug-adjacent claim language, and you will need to comply with MoCRA facility registration and product listing requirements (FDA MoCRA overview). Selling a Korean-market label as-is in the US is a common indie brand mistake that draws FDA warning letters.

Which of these three has the best clinical evidence? Alpha-arbutin has the broadest regulator-reviewed dossier because the EU SCCS has issued formal opinions on it. Ethyl ascorbyl ether has the most active peer-reviewed research pipeline because vitamin C biology is a busy academic area. Kojic acid (in various forms) has decades of literature but a more fragmented regulatory story. Which is "best" depends on whether your priority is regulatory defensibility, dermatology publication citations, or formulation cost.

Do I need a Korean ODM to source these? Can a US contract manufacturer make the same formula? US contract manufacturers can and do formulate with all three, but the ingredient sourcing chain, price envelope, and formulation experience typically favor a Korean ODM for a brightening-focused SKU. Korean ODMs have spent 15+ years optimizing these specific formulas because the MFDS functional cosmetic framework created a domestic market pull for them. That accumulated craft is real.

What about tranexamic acid, should I be using that instead? Tranexamic acid is a different class of active, it targets the inflammatory pathway of pigmentation rather than tyrosinase directly, and its per-percent cost at Korean ODMs is materially higher than the three discussed here. It fits a different brief: post-inflammatory hyperpigmentation, higher-price clinical positioning, or a specialty dark-spot serum. For a first mass-market brightening SKU, one of the three above is usually the more efficient choice. See our earlier deep dive at Tranexamic Acid in Korean Skincare for the trade-off.

Working with ALTA MEET

At ALTA MEET we help US indie beauty founders scope Korean ODM programs from quote-sheet review through launch, including translating the MFDS functional cosmetic framework into MoCRA-compliant US positioning. If you are scoping a brightening serum and want a second read on the Korean quote sheet before you sign, we run a 15-minute free gut-check for founders. Book a call with Liz.

Related pieces on the altameet blog you may find useful next:

• PDRN in Korean ODM Skincare: Sourcing, FDA, Cost (2026)
• KFDA vs FDA vs EU: Cosmetic Safety Standards (2026)
• Tranexamic Acid in Korean Skincare: Indie ODM Sourcing Guide (2026)

Key takeaways

• Alpha-arbutin, kojic acid dipalmitate, and ethyl ascorbyl ether are the three brightening actives Korean ODMs quote most often into indie US brand programs.
• All three sit on the MFDS whitening functional cosmetic list, but that regulatory pedigree does not port to US claims under MoCRA.
• Alpha-arbutin is the cheapest to formulate and the safest regulatory default; ethyl ascorbyl ether is the pragmatic vitamin C choice; kojic acid dipalmitate is the fermented-heritage story with the strongest ester-form stability track record.
• MoCRA claim language must stay on the appearance side of the cosmetic/drug line: "brighter", "even-tone", "reduces the look of dark spots", not "lightens" or "inhibits melanin".
• T